Why the study?
A major concern in the application of CRISPR/Cas9 is off-target effects causing unexpected, unwanted, or adverse genomic alterations.
This review highlights the methods for detecting and managing off-target effects in CRISPR/Cas9 gene editing, which is crucial for future gene therapy applications.
Answers are grounded in this paper and cite their sources.
Advances in off-target detection may enhance CRISPR safety for cardiovascular gene therapies; leaves open need for clinical validation.
Gene editing stands for the methods to precisely make changes to a specific nucleic acid sequence. With the recent development of the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system, gene editing has become efficient, convenient and programmable, leading to promising translational studies and clinical trials for both genetic and non-genetic diseases. A major concern in the applications of the CRISPR/Cas9 system is about its off-target effects, namely the deposition of unexpected, unwanted, or even adverse alterations to the genome. To date, many methods have been developed to nominate or detect the off-target sites of CRISPR/Cas9, which laid the basis for the successful upgrades of CRISPR/Cas9 derivatives with enhanced precision. In this review, we summarize these technological advancements and discuss about the current challenges in the management of off-target effects for future gene therapy.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: